Publications by authors named "Melda Dolan"
Article Synopsis
- TGF-β signaling is crucial for fetal heart development and heart repair, making its inhibitors require careful safety assessments in cancer treatments.
- In a study involving 79 cancer patients, the TGF-β inhibitor LY2157299 was given either alone or with lomustine, with extensive cardiovascular monitoring conducted throughout the treatment.
- Results showed no significant cardiovascular toxicities or damage, supporting further clinical trials of LY2157299 as a potential cancer therapy.
Objectives: The authors sought to define the risks versus benefits of ultrasound contrast agents in patients undergoing stress echocardiography.
Background: The Food and Drug Administration recently placed a "black box" warning on the ultrasound contrast agents Definity (Bristol-Myers Squibb Medical Imaging, Billerica, Massachusetts) and Optison (GE Healthcare, Princeton, New Jersey) after their use was temporally related to 4 deaths. The safety of contrast has not been systematically evaluated.